undamentalytics Newsletter
Sign in

Anavex Life Sciences Corp. (AVXL) stock

Add to watchlist

Add holding +

NASDAQ: AVXL Nasdaq Biotechnology Next results ~November 24, 2026

Anavex Life Sciences Corp. is a US-listed company in the biotechnology industry. Its financial year ends in September.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds86 adding, 88 cuttingOf 28 active managers that changed their stake, 17 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 24, 2026 (estimated)

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 21.0% while net income grew 73.0%: a 52pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Share dilution. Diluted shares rose 2.7% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 90% and a beta of 1.9 against the S&P 500.
  • Heavily shorted. 13.8% of the shares available to trade are sold short (9.8 days of average volume to cover).

Latest results

Earnings per share
$0.08 against an average estimate of -$0.08: beat by 200.0%
Share reaction
+4.2% in the first session after the results on August 25, 2026, against +0.3% for the S&P 500
Next report
November 24, 2026

Anavex Life Sciences' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-4.2%
  • 1 week-10.9%
  • 1 month-37.4%
  • This year-68.0%
  • 1 year-85.7%
  • 5 years-94.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

EPS (TTM, diluted)
$-0.15

Growth

Share count change
+2.7%

Earnings

Last results
August 25, 2026

News & updates

Updated November 3, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Announcement
  3. Announcement
  4. Shareholder vote
  5. Announcement
  6. Announcement
  7. Results
  8. Announcement
  9. Announcement
  10. Announcement
  11. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Anavex Life Sciences Corp. valuation models and calculator

No model value for Anavex Life Sciences Corp. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Anavex Life Sciences Corp. as an operating company, with every model that fits that kind of business. Cost of equity 10.7%: the 10-year Treasury yield (4.9%) plus a beta of 1.29 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no positive revenue in the latest twelve months
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Anavex Life Sciences Corp. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 24, 2026, before the open.

Analysts' consensus

No analyst estimates are published for Anavex Life Sciences Corp.: too few analysts cover it.

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.08 $0.08 +200.0%
Mar 2026 −$0.07 −$0.06 +14.3%
Dec 2025 −$0.11 −$0.06 +45.5%
Sept 2025 −$0.15 −$0.11 +26.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

1 analysts, Oct 2026
Buy1100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202611

Counts of recommendations published by analysts covering Anavex Life Sciences Corp., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
13.8%
of tradable shares
Days to cover
9.84
at average volume
Short interest, 1 month
−12%
to October 15, 2026
Held by institutions
40%
of shares
Held by insiders
1.7%
of shares
Employees
34
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
AVXL+221%−47%+1%+15%−67%−68%
Industry peers (median)−36%−57%−18%−29%−5%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
AVXL67%58%42%50%33%36%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
AVXL−42%−59%−57%−64%−77%−79%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 96% from June 28, 2021 to November 2, 2026. Getting back needed a 2432% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.14 – $7.74
From 52-week high
−85.3%
vs 50-day average
−45.7%
vs 200-day average
−62.9%
Volatility (1 year)
90%
Beta vs S&P 500
1.91

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 2 down
typical move ±8.4%
After a week
3 up, 3 down
typical move ±20.1%
After a month
5 up, 1 down
typical move ±14.8%
Results releasedNext dayS&P 500 next day5 days21 days
August 25, 2026 +4.2% +0.3% −7.7% −24.8%
July 30, 2026 +10.4% +2.4% +31.7% +20.1%
February 9, 2026 −3.4% +0.2% −1.5% +13.4%
November 25, 2025 +25.3% +1.6% +48.4% +18.2%
May 9, 2024 +2.7% +0.7% +21.3% +2.2%
December 28, 2020 −4.2% +0.7% −10.1% +10.3%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Dividends, buybacks and capital spending

Diluted share count
+2.7%
year over year

Who owns it

Funds buying and selling
Reported value
$95.9M
Institutions reporting
176
Shares held vs prior quarter
▼ 7.5%
Positions opened / closed
23 / 32

Top buyers and sellers, Q2 2026: 86 institutions bought and 88 sold ; the biggest buyer was Federated Hermes, Inc (+540K shares) and the biggest seller State Street Corp (−2.6M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $20.9M 8.1M 21.8% ▲ 5.9%
Vanguard Capital Management LLC $10.5M 4.1M 11.0% ▲ 4.9%
Two Sigma Investments, LP $7.9M 3.0M 8.2% ▼ 6.2%
Geode Capital Management, LLC $6.2M 2.4M 6.5% ▲ 10.0%
State Street Corp $5M 1.9M 5.2% ▼ 57.4%
Federated Hermes, Inc. $2.8M 1.1M 2.9% ▲ 101.4%
AQR Capital Management LLC $2.5M 963K 2.6% ▲ 27.2%
Vanguard Portfolio Management LLC $2.5M 949K 2.6% ▲ 21.1%
Summit Financial, LLC $2.4M 909K 2.5% ▼ 3.3%
Goldman Sachs Group Inc $2.3M 891K 2.4% ▲ 10.7%
Marshall Wace, LLP $2.3M 890K 2.4% ▲ 112.0%
Northern Trust Corp $2M 784K 2.1% ▲ 8.2%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Anavex Life Sciences Corp.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 2 trades and filings

No trades in Anavex Life Sciences Corp. disclosed in the last 12 months; 2 earlier trades on record.

  • Chris Jacobs(R-NY 27):Sale (full), $1,001 - $15,000, traded December 12, 2022, filed January 20, 2023
  • Chris Jacobs(R-NY 27):Purchase, $1,001 - $15,000, traded October 12, 2022, filed November 16, 2022

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

  • August 25, 2026
  • July 30, 2026
  • February 9, 2026
  • November 25, 2025
  • May 9, 2024
  • December 28, 2020

Recent SEC filings

Data status

When each part of this page on Anavex Life Sciences Corp. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Anavex Life Sciences Corp. in brief

What does Anavex Life Sciences Corp. do?
Anavex Life Sciences Corp. is a US-listed company in the biotechnology industry. Its financial year ends in September.
What is Anavex Life Sciences Corp.'s stock ticker?
Anavex Life Sciences Corp. trades under the ticker AVXL on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Anavex Life Sciences Corp.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Vanguard Capital Management LLC and Two Sigma Investments, LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
When is Anavex Life Sciences Corp.'s next earnings date?
Around November 24, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Anavex Life Sciences Corp. announces its own schedule.